Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 19/20 | 1.00 |
| ▸ | EGFR | P00533 | 3/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.66 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3373665 | 0.94 | ERBB2 (0.89) | ERBB2EGFRKCNH2 | |
| SCHEMBL3379126 | 0.94 | ERBB2 (0.89) | ERBB2EGFRKCNH2 | |
| SCHEMBL3376402 | 0.93 | ERBB2 (0.86) | ERBB2EGFRKCNH2 | |
| SCHEMBL3378329 | 0.93 | ERBB2 (0.86) | ERBB2EGFRKCNH2 | |
| SCHEMBL3380665 | 0.91 | ERBB2 (1.00) | ERBB2EGFRKCNH2 | |
| SCHEMBL3376026 | 0.91 | ERBB2 (1.00) | ERBB2EGFRKCNH2 | |
| SCHEMBL3375356 | 0.91 | ERBB2 (0.83) | ERBB2EGFRKCNH2 | |
| SCHEMBL3376585 | 0.89 | ERBB2 (0.89) | ERBB2EGFRKCNH2 | |
| SCHEMBL3375354 | 0.89 | ERBB2 (0.89) | ERBB2EGFRKCNH2 | |
| SCHEMBL3379173 | 0.89 | ERBB2 (0.81) | ERBB2EGFRKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1928861-B1 | 4- (IH-INDAZOL-5-YL-AMINO)-QUINAZOLINE COMPOUNDS AS ERBB RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2010-11-17 | — | — | EP | claimed |
| US-7820683-B2 | 4-(1H-indazol-5-yl-amino)-quinazoline compounds as erbB receptor tyrosine kinase inhibitors for the treatment of cancer | ASTRAZENECA AB (SE) | 2010-10-26 | — | — | US | claimed |
| US-20090048251-A1 | 4-(1H-INDAZOL-5-YL-AMINO)-QUINAZOLINE COMPOUNDS AS ERBB RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2009-02-19 | — | — | US | claimed |
| EP-1928861-B1 | 4- (IH-INDAZOL-5-YL-AMINO)-QUINAZOLINE COMPOUNDS AS ERBB RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2010-11-17 | — | — | EP | disclosed |
| US-7820683-B2 | 4-(1H-indazol-5-yl-amino)-quinazoline compounds as erbB receptor tyrosine kinase inhibitors for the treatment of cancer | ASTRAZENECA AB (SE) | 2010-10-26 | — | — | US | disclosed |
| US-20090048251-A1 | 4-(1H-INDAZOL-5-YL-AMINO)-QUINAZOLINE COMPOUNDS AS ERBB RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048251-A1 | 4-(1H-INDAZOL-5-YL-AMINO)-QUINAZOLINE COMPOUNDS AS ERBB RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ERBB2, ERBB4, ERBB3 | ERBB2 1/4885EGFR 5/4885KCNH2 3904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.